Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock

Posted by Brenda Bartman on Aug 17th, 2026

Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) CEO Shao-Lee Lin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the completion of the sale, the chief executive officer owned 724,253 shares of the company’s stock, valued at $19,627,256.30. This trade represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total value of $522,543.96.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock opened at $34.20 on Monday. The business’s 50 day moving average price is $29.50 and its 200 day moving average price is $146.00. The company has a market cap of $143.64 million, a price-to-earnings ratio of -1.27 and a beta of 2.47. Cue Biopharma, Inc. has a one year low of $4.97 and a one year high of $45.50.

Cue Biopharma (NASDAQ:CUE – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 482.58%. The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million.

Wall Street Analysts Forecast Growth

CUE has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Get Our Latest Stock Analysis on Cue Biopharma

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Cue Biopharma in the 2nd quarter valued at approximately $83,000. Persistent Asset Partners Ltd purchased a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $389,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cue Biopharma in the 2nd quarter valued at approximately $722,000. ADAR1 Capital Management LLC acquired a new stake in Cue Biopharma in the 2nd quarter valued at approximately $1,742,000. Finally, BlackRock Inc. purchased a new stake in Cue Biopharma in the second quarter valued at approximately $1,824,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

(Get Free Report)

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.